Acute Myocardial Infarction, Atrial Fibrillation New Onset
Conditions
Keywords
Acute Myocardial Infarction, New-Onset Atrial Fibrillation, Burden, Prospective, Cardiovascular Outcomes
Brief summary
To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.
Detailed description
Our previously designed single-center retrospective cohort study (NCT03533543) suggested that patients with a greater burden of NOAF complicating AMI were challenged by a poor prognosis. In the present study, we aim to design a multicenter, prospective, hospital-based registry to validate the preceding findings. We plan to enroll patients who were admitted for AMI in 9 tertiary medical centers from Shanghai, Henan, and Zhejiang provinces and developed NOAF during the index hospitalization. All eligible patients' demographics, cardiovascular risk factors, comorbidities, laboratory tests, echocardiography data, angiography data, and medications will be collected. NOAF burden is calculated by dividing the total AF duration by the total continuous electronic monitoring (CEM) duration. Other NOAF related characteristics, such as AF pattern, AF frequency, and symptomatic or silent AF, and the longest AF episode duration will also be evaluated. All patients who are discharged alive will be followed for at least 2 years and cardiovascular outcomes will be recorded.
Interventions
All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
Sponsors
Shanghai 10th People's Hospital
Shanghai Tong Ren Hospital
Kaifeng Central Hospital
Shanghai 7th People's Hospital
The First Affiliated Hospital of Zhengzhou University
Luoyang Central Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Adult patients (\>18 years old); * Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization; * Patients must have received in-hospital CEM for at least 5 days; * Patients must give informed consent.
Exclusion criteria
* Patients with a medical history of pre-existing AF; * Patients with a medical history of rheumatic valvular disease; * Patients with a medical history of sick sinus syndrome; * Patients undergoing emergent coronary artery bypass surgery; * Patients who suffer malignant tumors with an expected lifetime less than 1 year ; * Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved; * Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI; * Patients who have died during the index hospitalization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause death | up to 1 year | Death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular death | up to 1 year | All deaths without a clear non-cardiovascular cause would be classified as cardiovascular deaths |
| Heart failure hospitalization | up to 1 year | Heart failure hospitalization is defined as a minimum of an overnight hospital stay of a participant who presented with symptoms and signs of HF or received intravenous diuretics |
| Recurrent myocardial infarction | up to 1 year | Recurrent myocardial infarction is defined as the myocardial infarction episode that occurs after 28 days following the index AMI hospitalization. |
| Ischemic stroke | up to 1 year | Ischemic stroke is defined as the presence of a new focal neurologic deficit thought to be ischemic in origin, with signs or symptoms lasting\>24h. |
| Major bleeding | up to 1 year | Bleeding event with a Bleeding Academic Research Consortium (BRAC) classification of types 3 or 5 |
Countries
China
Contacts
CONTACTJiachen Luo, M.D., Ph.D.
PRINCIPAL_INVESTIGATORYidong Wei, M.D., Ph.D.
Department of Cardiology, Shanghai Tenth People's Hospital
Outcome results
None listed